Tranexamic acid to elderly patients undergoing combined AVR and CABG surgery.
- Conditions
- We will investigate whether tranexamic acid given as a bolus injection at the start of surgery followed by a continuous infusion during surgery reduces postoperative bleeding in patients above 70 years undergoing combined AVR and CABG surgery.
- Registration Number
- EUCTR2006-004561-34-NO
- Lead Sponsor
- St. Olavs Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
|Female and male patients above 70 years who are scheduled for combined AVR and CABG surgery.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Patients below 70 years.
Patients undergoing other cardiac surgery than combined AVR and CABG surgery.
Patients who are not pretreated with acetylsalicylic acid.
Patients with known defects in the hemostatic system.
Patients pretreated with NSAIDs, clopidogrel, heparin, LMWHs, or warfarin.
Patients treated with systemic steroids.
Patients with a creatinine level above 140 micromol/l.
Patients with an INR above 1.5.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Investigate whether tranexamic acid given intraoperatively reduces postoperativ bleeding and the use of blood components after cardiac surgery.;Secondary Objective: Invetsigate whether tranexamic acid reduces fibrinolysis during and after cardiac surgery.;Primary end point(s): Postoperative bleeding, postoiperative loss of hemoglobin, postoperative use of blood components after cardiac surgery.
- Secondary Outcome Measures
Name Time Method